Article info
PDFOriginal research
Arrogance of ‘but all you need is a good index finger’: A narrative ethics exploration of lack of universal funding of PSA screening in Canada
- Correspondence to Dr Jeff Nisker, Obstetrics and Gynaecology, Western University, London, ON N6A 3K7, Canada; jeff.nisker{at}lhsc.on.ca
Citation
Arrogance of ‘but all you need is a good index finger’: A narrative ethics exploration of lack of universal funding of PSA screening in Canada
Publication history
- Received August 1, 2019
- Revised September 9, 2019
- Accepted October 8, 2019
- First published October 29, 2019.
Online issue publication
November 15, 2022
Article Versions
- Previous version (15 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
- A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening—a qualitative analysis
- Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer?
- Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
- Primary goals, information-giving and men’s understanding: a qualitative study of Australian and UK doctors’ varied communication about PSA screening
- Prostate cancer screening and the management of clinically localized disease
- Screening for prostate cancer remains controversial
- Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening
- Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
- Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study